/

Empresas

Ky

No verificado

Kyowa Kirin

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina Salud BienestarSalud

18 Comunicados de prensa

Ver todos los comunicados de prensa

21/07/2026

Industria

Salud

Biotecnología

Sanidad

Farmacéutica

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Fuente

Editor

1.00

0

30/06/2026

Farmacéutica

Medicina Salud Bienestar

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome

Fuente

Editor

1.00

0

29/06/2026

Farmacéutica

Medicina Salud Bienestar

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

Fuente

Editor

1.00

0

10/06/2026

Farmacéutica

Medicina Salud Bienestar

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

Fuente

Editor

1.00

0

24/04/2026

Biotecnología

Anuncios breves

Medicina Salud Bienestar

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Fuente

Editor

1.00

0

03/03/2026

Anuncios breves

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

Fuente

Editor

1.00

0

31/01/2026

Farmacéutica

Medicina Salud Bienestar

Anuncios breves

Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique

Fuente

Editor

1.00

0

31/01/2026

Farmacéutica

Medicina Salud Bienestar

Anuncios breves

Kyowa Kirin recupera el control del programa de desarrollo y comercialización de rocatinlimab, demostrando un firme compromiso para abordar la elevada necesidad médica no cubierta en la dermatitis atópica

Fuente

Editor

1.00

0

30/01/2026

Farmacéutica

Medicina Salud Bienestar

Anuncios breves

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

Fuente

Editor

1.00

0

11/12/2025

Mercado laboral

Industria

Finanzas

Biotecnología

Medicina - Varios

Asociaciones/Profesionales

Sanidad

Salud

Farmacéutica

Oncología

Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0